We estimate there are probably about 150 to 200 products that could be put into this platform technology. Right now our priorities are being driven primarily by the interest of potential licensees. We would like to have enough capital to be able to take compounds all the way through to FDA approval prior to licensing. Most formulation development companies seem to be focusing it on sustained release or delivery to the lung or through the nose. There are several companies working on Buccal patches and one company in Canada is apparently working on a Buccal spray using micelles.
Micelles are little fatty globules precipitated around the drug to protect it.
Unfortunately, from our point of view, the protection also delays the release and the absorption through of the Buccal mucosa. As a result, most of the drug probably goes down into the stomach and is absorbed in the stomach or intestine instead of the mouth. As far as we know, Flemington is the only company delivering drugs in solution into the buccal cavity where they are immediately available for absorption. Again, as far as I know, Flemington is the only company that achieves this very rapid rise in blood levels. Give us an assessment of your management team at this point.